Plasmacytoid urothelial carcinoma is rare and aggressive, with poor outcomes and challenges in accurate staging. National and institutional data reveal discrepancies in chemotherapy use and disease ...
In this video, Fed Ghali, MD, highlights key findings from the study, “Evaluating Clinical Outcomes and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback